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Activated, TIMP-free MMPs
MMP inhibitor-tethered resins provide a method for
detection of activated MMPs in tissues [1]. These mea-
surements will help to elucidate in situ mechanisms of
MMP activation, further our understanding of the tu-
mor microenvironment, and facilitate development of
MMP-inhibitor therapy.
Matrix metalloproteinases (MMPs) are a large family of
zinc-dependent endoproteases that have been impli-
cated in many physiologic and pathologic processes.
This field of scientific interest emerged in 1962 from
the discovery of interstitial collagenase (later renamed
MMP-1) as a result of experiments designed to explain
collagen remodeling during tadpole metamorphosis
[2]. Basic MMP research for the next three decades fo-
cused on the activation of MMPs and the ensuing degra-
dation of extracellular matrix components (collagens,
laminin, fibronectin, etc.) [3]. Activation of MMPs is
achieved by removal of the N-terminal prosequence of
w80 amino acids by a two-step process. The initial
cleavage occurs in the accessible ‘‘bait’’ region located
between the first and second a helix in the propeptide
domain. This cleavage destabilizes the interaction of
the propeptide with the catalytic domain, leading to a fi-
nal cleavage often occurring as a bimolecular, autopro-
teolytic event. Clinical interest in the role of MMPs in
physiologic and pathologic processes gradually mush-
roomed, and now exceeds more than 1000 publications
per year.
High tissue levels of MMP-1, -2, -3, -7, -8, -9, -11, -13,
and -14 (MT1-MMP) have been demonstrated in many
types of human cancer; correlation with poor clinical
outcome has been reported. Not only are MMPs in-
creased in the tumor cells, but they are also increased
in stromal (fibroblasts, endothelial cells) and inflamma-
tory cells within tumors. The contribution of stromal
MMPs to tumor progression is hotly debated. Increased
tissue levels of MMPs have also been identified in in-
flammatory diseases including arthritis, colitis, peri-
odontitis, atherosclerosis, and cerebrovascular disease.
(Interested readers are referred to relevant review arti-
cles [4–9].)
In vivo activity of MMPs is rigidly controlled at several
levels. These enzymes are usually expressed in low
amounts, and their transcription is tightly regulated
[10]. MMP-2 is the exception to the general rule and is
constitutively produced and activated on the cell sur-
face by membrane type 1-MMP (Figure 1; MT1-MMP).
Activation of other secreted MMPs also occurs by re-
moval of the prodomain by proteolytic or nonproteolytic
mechanisms that are not well understood. MMPs that
contain a furin-like recognition domain in their propep-
tide (MMP-11, MMP-28, and MT 1-MMP) are activated
intracellularly. Once activated, MMPs are further regu-
lated by endogenous inhibitors, autodegradation, andselective endocytosis [11]. In normal physiology, high
extracellular concentrations of tissue inhibitors of metal-
loproteinases (TIMP-1, -2, -3, and -4) and a2-macro-
globulin (a2M) oppose random MMP activation. Most
cells secrete both MMPs and TIMPs, as well as activa-
tors of MMPs. Hence, the function of activated MMPs
tends to be limited to short bursts of time in the pericel-
lular microenvironment. MMPs bound to the cell surface
are partially protected from TIMP inhibition.
The simplicity of thinking about MMPs solely as extra-
cellular matrix degrading enzymes and TIMPs solely as
inhibitors of these processes has recently been eroded
by the recognition of numerous other important roles
for these proteins. Extracellular matrix-localized growth
factors, e.g., basic fibroblast growth factor (bFGF),
transforming growth factor b (TGF-b), as well as cell sur-
face bound precursors of growth factors, are released
as functional molecules following cleavage by activated
MMPs. Growth factor receptors, such as fibroblast
growth factor receptor 1, interleukin-2 receptor a, and
integrins can be cleaved from the cell surface by MMPs.
Other examples of substrates cleaved by MMPs include
proteins involved in apoptosis, angiogenesis, cell migra-
tion, and evasion of immune surveillance [4–9]. Expo-
sure of cryptic sites that contain signaling information
for responsive cells is another common theme of
MMPs [12]. Through these pathways, MMP cleavage
would appear to facilitate cancer invasion and metasta-
sis; however, cleavage of some substrates can interfere
with cancer dissemination, i.e., MMP-induced cleavage
of plasminogen results in generation of angiostatin, an
inhibitor of tumor angiogenesis [4–9]. The major differ-
ence between physiologic processes and dissemination
of cancer cells seems to be one of regulation.
MMP expression profiles have been reported to be
useful in explicating various disease processes [13].
Yet, the critical question vexing scientists for the past
decade is: Does the presence of high tumor concentra-
tions of MMPs indicate that they have a causative role in
cancer progression/dissemination? As repeatedly em-
phasized, correlation does not necessarily mean causa-
tion [14]. However, measurement of MMPs in tissues is
not trivial. A practical problem in quantifying levels of
MMPs in clinical samples relates to genetic differences
in MMP expression. Additionally, specific MMPs have
different functions depending on the stage of cancer
and the local milieu of the cancer cells.
Emphasis has been placed on the importance of ac-
tive rather than total MMP levels in tumors [15]. How-
ever, technical problems in the identification of acti-
vated MMPs in tissues have limited this assessment.
The fact that activated MMPs have not been detected
in the blood of cancer patients suggests that endoge-
nous inhibitors rapidly bind and inactivate mature prote-
ases in tissues and blood [7]. The high ratio of MMPs to
TIMPs in cancer tissue specimens has been proposed to
reflect dominant proteolytic activity and has been corre-
lated with poor prognosis [3–7].
Gelatin substrate zymography has been used widely
as a sensitive, inexpensive technique to detect both
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348MMP-2 and -9 and to distinguish between latent and ac-
tivated proteases. However, this technique does not
permit distinction between free MMP and active prote-
ase bound to TIMP or a2M. Enzyme-linked immunosor-
bent assays are reliable, sensitive, and available com-
mercially, but do not distinguish between active and
latent MMPs [7]. DNA microarray, real-time RT-PCR,
and proteomic approaches have more recently been
proposed as techniques to target the profiling of prote-
ases in cancer [16]. These technologies are limited by
not addressing functional activity of MMPs.
In this issue of Chemistry & Biology, Hesek et al. [1]
report the comprehensive design and characteriza-
tion of a resin-immobilized potent broad-spectrum syn-
thetic MMP inhibitor for the selective detection of active
forms of MMPs in experimental samples. Only the free
active MMPs, and not the zymogens or MMP/TIMP
complexes, were bound specifically to the resin. On ex-
amination of human tissue, active (free) MMP-2 and
MMP-14 were detected in cancerous, but not in benign,
human tissue extracts. The authors propose that the
identification of the active MMP profile for individual
cancer types will help to target specific MMPs on an in-
dividual basis, hence encouraging future development
of specific/selective inhibitory drugs for treatment of
Figure 1. Cartoon Describing the Competition between Exogenous
MMP Inhibitor-Tethered Resin Binding and Endogenous TIMP Bind-
ing of Activated MMP-2 in the Extracellular Space
Following propeptide cleavage, the catalytic site of MMP-2 is
exposed and capable of binding to inhibitors. For simplicity, the
triplex formed on the cell surface consisting of MT1-MMP,
TIMP-2, and proMMP-2 leading to generation of activated MMP-2
is omitted.cancer. Based on the data presented, it would appear
that a fluorescent immobilized resin approach might
also be applicable for in situ detection of active MMPs
in living tissue. This type of approach has the poten-
tial to illuminate the mystery of pericellular protease
activation.
As an example of tissue specimens readily accessible
for future study, neutrophils and macrophages have
high constitutive levels of MMPs and other proteases,
which are released at sites of tissue injury and repair.
These inflammatory cells are prominently displayed in
tumor stroma. Detection of activated MMP-9 following
degranulation of neutrophils provides a model for how
the currently disclosed technology may be useful in ex-
panding our understanding of the pathophysiology of
MMPs.
The type of translational research presented in Hesek
et al. is sorely needed to reinvigorate pharmaceutical in-
dustry interest in developing specific MMP inhibitors for
treatment of cancer and inflammatory diseases. The au-
thors wisely caution that a variety of factors, including
tissue extraction procedure and sample storage, will af-
fect detection of active MMPs in tissue samples. How-
ever, these technical problems may limit widespread uti-
lization of metalloproteinase inhibitor-tethered resin
examination of clinical tissues for diagnosis, staging,
and prognosis of cancer. One alternative is the develop-
ment of techniques to identify the cleavage products re-
leased following activation of latent MMPs [7]. These
‘‘footprints’’ remaining after MMP activation include
the N-terminal and C-terminal activation products re-
leased from MMPs themselves [17] or cleaved from ex-
tracellular matrix proteins.
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New Images Evoke
FAScinating Questions
Two recent papers in Science reported the X-ray struc-
tures of the large, organizationally distinct animal and
fungal fatty acid synthases at 5 A˚. These new struc-
tural insights have unexpected implications for en-
zyme function for the other ‘‘iterative’’ and ‘‘assembly
line’’ megasynthases.
Five years ago, we saw the bacterial ribosome at 5 A˚ res-
olution [1–6]. Now, two landmark papers appearing re-
cently in Science present the first views of two fatty
acid synthases (FASs) at similar resolution, another im-
portant cellular macromolecular machine. Through a
complex catalytic mechanism involving decarboxylative
condensation, reduction,anddehydration activities,FAS
produces long-chain fatty acids from acetyl-CoA and
malonyl-CoA units. The protein in mammals is encoded
by a single gene, consists of seven catalytic domains,
and is functional as a homodimer (a2). In surprising con-
trast, analogous domains in fungi are distributed be-
tween two subunits, and a giant, structurally distinct
a6b6 barrel carries out the corresponding reactions, al-
though it releases its fatty acid product as the CoA ester
rather than the free acidas in the caseof mammalian FAS.
The breakthrough in the 3D structural elucidation of
animal FAS provides new insights and resolves the on-
going controversy over the structure of the enzyme.
The original model formulated in the 1980s envisioned
the two a-subunits of FAS oriented in an extended anti-
parallel arrangement in which a noncatalytic central core
stabilized the dimeric structure [7]. Stuart Smith and co-
workers proposed a revision of this view in accordance
with key biochemical findings and EM data highlighting
both intra-and interfunctional interactions of the sub-
units [8, 9]. Although the resolution of the current crystal
structure is insufficient to trace the complete backbone
of the individual subunits, the authors have fit atomic-
resolution structures of homologous individual bacterial
proteins into the electron density map of mammalian
FAS to reveal the location of most of the functional do-
mains. The model proposed by the authors depicts
two coiled subunits oriented head-to-head with paired,
centrally located KS domains stabilizing the dimer in15. Brown, P.D., Bloxidge, R.E., Anderson, E., and Howell, A. (1993).
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close agreement with the predictions of Smith. The X-
shaped model consists of a main body composed of
the ER and KS dimers and the pseudodimeric DH pairs,
while the monomeric KR and MT domains are located
peripherally at the top and bottom of the model, respec-
tively (Figure 1, left). The active sites of the two sets of
catalytic domains are oriented facing each of the two lat-
eral clefts in the structure, thus forming two asymmetric
reaction chambers. While ambiguities exist in the struc-
ture, for example, the key ACP and TE domains cannot
be clearly discerned, the crystal structure presents
a model that largely accommodates previous biochem-
ical findings.
As with the mammalian enzyme, EM analysis has pro-
vided a global view of fungal FAS. While the limits of res-
olution did not permit localization of individual domains,
it did allow general placement of the a and b subunits
within the a6b6 barrel [10, 11]. The X-ray structure has
now provided a sharper view in which active sites have
been approximated within most of the catalytic domains
in the enormous 230 3 260 A˚ cage-like superstructure
(Figure 1, right). Three sets of active sites face inward
within two identical reaction chambers. Each chamber
contains openings as large as 25 A˚, permitting sub-
strates and products to passively diffuse in and out as
their CoA esters. The structure determined at lower res-
olution (8 A˚) identified a potential attachment region for
the ACP located in the interior and accessible for inter-
actions among the domains of multiple subunits, which
agrees well with earlier biochemical studies [12].
Interestingly, the order of catalytic domains in animal
FAS parallels the bacterial type I modular, or ‘‘assembly
line,’’ polyketide synthases (PKSs) responsible for the
biosynthesis of a wide variety of macrolide and poly-
ether natural products as, for example, erythromycin
[13, 14]. The type I modular PKS model of intertwined di-
meric helices deduced by Peter Leadlay and Jim Staun-
ton has proved prescient in guiding thoughts not only
about modular PKSs, but also in unifying revision of
the long-held view of mammalian FAS head-to-tail di-
merization [14, 15]. Nonribosomal peptide synthetases
(NRPSs), a parallel universe of giant, modular enzymes
that make, for example, the precursors of penicillin
and vancomycin, are organized and function in an anal-
ogous manner [16, 17]. The synthetic potential of PKSs
and NRPSs is adroitly combined in Nature to synthesize
metabolites like epothilone and rapamycin [18].
